By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...
A Phase III clinical trial led by Neeraj Agarwal, MD, FASCO, senior director of clinical research at Huntsman Cancer ...
A novel theranostic approach that targets RET -- a newly identified biomarker for neuroendocrine prostate cancer enables high ...
Results of a multicenter clinical trial found that adding the investigational adenoviral-based viral immunotherapy aglatimagene besadenovec (alglatimagene, CAN-2409) to standard radiation therapy ...
Increased urinary urgency Frequent nighttime awakenings to urinate A slow or weak urinary flow Blood in the urine or semen As prostate cancer progresses and spreads to other areas of the body, it may ...